These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32046804)

  • 1. Evaluation of immunisation strategies for pertussis vaccines in Jinan, China - an interrupted time-series study.
    Liu TC; Zhang J; Liu SQ; Yin AT; Ruan SM
    Epidemiol Infect; 2020 Feb; 148():e26. PubMed ID: 32046804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whooping cough surveillance in France in pediatric private practice in 2006-2015.
    Guiso N; Levy C; Romain O; Guillot S; Werner A; Rondeau MC; Béchet S; Cohen R
    Vaccine; 2017 Oct; 35(45):6083-6088. PubMed ID: 28974408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand.
    Radke S; Petousis-Harris H; Watson D; Gentles D; Turner N
    Vaccine; 2017 Jan; 35(1):177-183. PubMed ID: 27866766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Specificity Following a Recent
    Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
    Front Immunol; 2019; 10():1364. PubMed ID: 31275314
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced risk of pertussis in whole-cell compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses.
    Sheridan SL; Ware RS; Grimwood K; Lambert SB
    Vaccine; 2015 Sep; 33(39):5027-30. PubMed ID: 26297874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak.
    Witt MA; Katz PH; Witt DJ
    Clin Infect Dis; 2012 Jun; 54(12):1730-5. PubMed ID: 22423127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pertussis vaccination approaches: en route to protect newborns?
    Locht C; Mielcarek N
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).
    Plans P; Toledo D; Sala MR; Camps N; Villanova M; Rodríguez R; Alvarez J; Solano R; García-Cenoz M; Barrabeig I; Godoy P; Minguell S
    Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):2059-2067. PubMed ID: 27612470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccines in China.
    Wang L; Lei D; Zhang S
    Vaccine; 2012 Nov; 30(50):7174-8. PubMed ID: 23084855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia.
    Kurova N; Timofeeva EV; Guiso N; Macina D
    Vaccine; 2018 Dec; 36(52):7936-7942. PubMed ID: 30448334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.
    Lavine JS; Bjørnstad ON; de Blasio BF; Storsaeter J
    Vaccine; 2012 Jan; 30(3):544-51. PubMed ID: 22119924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pertussis: An unresolved problem.
    Esposito S; Principi N
    Hum Vaccin Immunother; 2018; 14(10):2452-2459. PubMed ID: 29856680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of pertussis.
    Tan T; Trindade E; Skowronski D
    Pediatr Infect Dis J; 2005 May; 24(5 Suppl):S10-8. PubMed ID: 15876918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?
    van der Maas NA; Mooi FR; de Greeff SC; Berbers GA; Spaendonck MA; de Melker HE
    Vaccine; 2013 Sep; 31(41):4541-7. PubMed ID: 23933365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
    Elomaa A; He Q; Minh NN; Mertsola J
    Vaccine; 2009 Sep; 27(40):5443-9. PubMed ID: 19628060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune persistence after pertussis vaccination.
    Chen Z; He Q
    Hum Vaccin Immunother; 2017 Apr; 13(4):744-756. PubMed ID: 28045580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience and challenges on influenza and pertussis vaccination in pregnant women.
    Madhi SA; Nunes MC
    Hum Vaccin Immunother; 2018; 14(9):2183-2188. PubMed ID: 30024822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.